On Monday the S&P/ASX 200 Index (ASX: XJO) started the week in a disappointing fashion. The benchmark index fell 0.9% to 6,697.2 points.

Will the market be able to bounce back from this on Tuesday? Here are five things to watch:

ASX 200 expected to rise.

It looks set to be a better day for the Australian share market on Tuesday. According to the latest SPI futures, the ASX 200 is poised to open 4 points higher this morning. This is despite a weak start to the week on Wall Street. In late trade the Dow Jones is down 0.35%, the S&P 500 has fallen 0.65%, and the Nasdaq has tumbled 1% lower.

Mesoblast on watch.

The Mesoblast limited (ASX: MSB) share price was a strong performer on Monday and jumped 14% higher. This followed the release of a positive announcement which revealed that its rexlemestrocel-L drug provides a reduction in heart attacks, strokes and cardiac death in patients with chronic heart failure. With the company’s US listed shares jumping 37% overnight on the news, its ASX listed shares may have some catching up to do today.

Oil prices mixed.

Energy producers including Beach Energy Limited (ASX: BPT) and Woodside Petroleum Limited (ASX: WPL) will be on watch after a mixed night for oil prices. According to Bloomberg, the WTI crude oil price rose 0.15% to US$52.33 a barrel and the Brent crude oil price has fallen 0.35% to US$55.79 a barrel.

Gold price rebounds.

It could be a better day for gold miners such as Newcrest Mining Limited (ASX: NCM) and St Barbara Ltd (ASX: SBM) after the gold price rebounded from Friday’s selloff. According to CNBC, the spot gold price is up 0.75% to US$1,849.10 an ounce. Traders appear to believe it was oversold on Friday when it dropped over 4%.

Zip update.

Second time lucky? Zip Co Ltd (ASX: Z1P) didn’t release its second quarter update as was largely expected on Monday, so today could be the day. Investors will no doubt be keen to see how the company performed during the all-important holiday season shopping period and if there has been any impact from growing industry competition.

More reading

• ASX 200 drops 0.9%
• Mesoblast (ASX:MSB) share price soars 14% on clinical trial results
• Broker thinks these 6 ASX energy shares could go higher
• Why the QBE (ASX:QBE) share price is in focus today
• ASX 200 down 0.4%: Afterpay tumbles, bank shares lower, gold miners crash

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of ZIPCOLTD FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post 5 things to watch on the ASX 200 on Tuesday appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/2LDWQ6L

The A2 Milk Company Ltd (ASX: A2M) share price was out of form on Monday and tumbled lower again.

The infant formula and fresh milk company’s shares dropped 3% to $10.62.

This means the a2 Milk share price is now down almost 50% from its 52-week high of $20.05.

Why is the a2 Milk share price sinking lower?

Investors have been selling the company’s shares over the last few months after COVID-19 had a negative impact on its sales and profits.

After benefiting greatly from panic buying and pantry stocking at the height of the pandemic, demand for its infant formula has softened over the last couple of quarters.

But the greatest impact has come in the daigou channel. This is where Chinese tourists and students buy products and send them back to China at inflated prices.

With international travel coming to a standstill, daigou sales have fallen heavily and put a big dent in the company’s earnings. In fact, the extent of the decline was even greater than expected and led to a2 Milk having to downgrade its guidance recently.

The company is expecting to deliver revenue of NZ$670 million in the first half of FY 2021. This is a 7.5% to 13.5% reduction on its previous guidance range of NZ$725 million to NZ$775 million.

Whereas for the full year, management now expects revenue to be in the range of NZ$1.4 billion to NZ$1.55 billion. The mid point of this guidance range is down 18% to 22.3% from its previous guidance range of NZ$1.8 billion to NZ$1.9 billion.

The company has also lowered its margin expectations and is now forecasting an earnings before interest, tax, depreciation and amortisation (EBITDA) margin of 26% to 29% for FY 2021. This is down from 31% previously.

Based on the mid point of both guidance ranges, this represents EBITDA of NZ$405.6 million in FY 2021. This would be down a sizeable 26.2% from FY 2020’s EBITDA of $549.7 million.

What else is weighing on its shares?

Also weighing on its shares has been a recent broker note out of Ord Minnett.

According to the note, the broker has retained its lighten rating and lowered its price target on the company’s shares to $9.90.

It reduced its price target and lowering its earnings estimates to reflect the tough trading conditions it is facing.

One possible positive, though, is that the company is sitting on a sizeable cash balance. With its share price trading close to a 52-week low, the broker has suggested that capital management initiatives could be considered.

More reading

• These are the 10 most shorted shares on the ASX
• Why a2 Milk, AVZ Minerals, Nanosonics, & Premier Investments are dropping lower
• Here’s why the A2 Milk (ASX:A2M) share price was hammered in 2020
• These are the 10 most shorted shares on the ASX
• These were the best performing ASX 200 shares last week

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended A2 Milk. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Why the a2 Milk (ASX:A2M) share price is sinking lower again appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3bt7o39

The ASX materials sector dipped a collective 1.06% today and these 3 mining companies – all with strong buy ratings – fell right along with it. Let’s take a closer look. 

Westgold Resources Ltd (ASX: WGX) 

The Westgold Resources share price took an 8.65% hit today, closing at $2.43. This is in contrast to the company’s previous six-month performance which has seen Westgold shares shoot close to 13% higher. 

According to its investor presentation in December for the financial year ending 30 June 2020, the company boasted a 131% gain in its profit per share. Revenue also zoomed up, increasing 18% to $492.3 million for the period.

The Institutional Brokers Estimates System (IBES) currently rates Westgold Resources a strong buy with a positive outlook. 

Perseus Mining Limited (ASX: PRU)

Perseus Mining also dropped more than 8% to close at $1.19. The mining company finished 2020 as one of the all-around S&P/ASX 200 Index (ASX: XJO) top performers for 2020.

Fortunately for Perseus, the company recently announced pouring its first gold 5 weeks ahead of schedule at its Yaouré Gold Mine in West Africa. This supports the company’s expectation to ship its first gold from the Yaouré mine site during the March 2021 quarter.

Similar to Westgold, the IBES currently rates Perseus Mining a strong buy with a positive outlook. 

Silver Lake Resources Limited (ASX: SLR)

Silver Lake Resources also took a hit today, sliding 5.69% to close at $1.74. Some may consider it just a slight dent given the company has roared 30% higher over the previous 12-month period. 

In its most recent quarterly activities report, Silver Lake reported a quarterly group production of 62,262 ounces of gold along with 424 tonnes of copper. The company also invested $6.6 million in exploration during the reported quarter to “advance high-grade projects within established and proven mineralised corridors proximal to established infrastructure”. 

Silver Lake’s current status with the IBES is a strong buy rating with a neutral outlook.

More reading

• ASX 200 down 0.4%: Afterpay tumbles, bank shares lower, gold miners crash
• ASX 200 rises 0.7% on Friday
• ASX 200 rose 1.6%
• Why Nick Scali, Nitro Software, Silver Lake, & Xero shares are dropping lower
• Do ASX mining companies carry the Australian share market?

Motley Fool contributor Gretchen Kennedy has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post These 3 ASX mining companies closed lower today appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3nCahRD

The Vection Technologies Ltd (ASX: VR1) share price retreated from an intraday high of 14.5 cents to close flat at 13.5 cents today – the same price it opened at this morning. This comes after the tech company announced the launch of an augmented and mixed reality (XR) interface for computer aided design (CAD) software through its 2021 Mindesk suite.

In today’s release, Vection said it will officially launch its Mindesk suite at the world’s biggest tech stage, CES 2021. The annual event brings the biggest names together to display their latest technology. It is being conducted online through the organiser’s media hub this year due to COVID-19.

Mindesk in a nutshell

Mindesk is a Vection subsidiary based in California that develops a real-time 3D design platform for use by designers, architects, engineers and CAD users.

The company enables users to design projects from CAD through a XR interface without the need to export. In addition, users can seamlessly switch their workflow between XR and desktop, editing and collaborating on demand.

New Mindesk 2021 suite

Previously, Mindesk’s Live Link supported the use of CAD software in a virtual reality environment, negating the need for programming skills and time-consuming export and configuration processes.

However, with the latest Mindesk release, the platform now includes Microsoft Hologens 2, Varjo XR1, and Varjo XR3. This new interface lets engineers and designers to place a virtual hologram of their model next to their workstation. The program is operated by mouse and keyboard, or by a 6DOF XR controller.

Developed to meet demanding requirements in the digital work space, Vection said that Mindesk XR application was “a milestone breakthrough”. Users can project the image which will allow them to take note of 3D assemblies, simulations, or point clouds.

One of many potential applications that Mindesk can be integrated within is the automotive industry. Modelling a 3D car in XR can effectively cut significant time in any rework for design concepts, thus bringing the product faster to market.

Management commentary

Vection director and Mindesk subsidiary CEO Gabriele Sorrento, said:

VR has been increasingly accepted by enterprises in the past two years. However, Mixed Reality now offers the opportunity to reach a wider professional audience.

We directed our efforts at breaking down the latest barriers of adoption of VR. The natural blend of mixed reality with existing professional tools and practices makes the transition to the XR not just seamless, but undelayable.

Vection managing director Gianmarco Biagi, added:

We are pleased to participate in the world’s biggest annual consumer electronics show, the CES 2021, presenting the breakthrough integration of XR in the Vection Technologies’ Mindesk software, a pivotal advancement of the company’s strategy around disruptive tools for design and engineering.

As the company progresses its global growth strategy, it continuously strives to develop disruptive technologies to cement a unique software suite, generating value for all stakeholders, toward wider product adoption in a fast-pacing high growth market segment.

More reading

• Why the Vection (ASX:VR1) share price has surged 9% today

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post What happened to the Vection (ASX:VR1) share price today? appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/2MRP0qG

If you’re wanting to construct a balanced portfolio, having a few blue chip ASX shares in there could be a smart move.

This is because blue chips tend to be companies that are well-known, long-established, and have strong financial positions. In other words, they are not going anywhere any time soon and should allow investors to make long term investments that benefit from compounding.

With that in mind, listed below are two ASX blue chip shares that come highly rated:

Cochlear Limited (ASX: COH)

The first blue chip to look at is Cochlear. It is one of the world’s leading hearing solutions companies and has delivered strong sales and profit growth over the last decade.

The good news is Cochlear appears well-positioned to continue this trend over the next decade. This is thanks to its strong market position, leading technology, the industry’s high barriers to entry, and its exposure to the ageing populations tailwind.

In respect to the latter, by 2050 there are forecast to be 1.5 billion people over the aged of 65. This will be almost triple the number of over 65s in 2010 and bodes well for demand for its product portfolio.

Analysts at Macquarie are fans of the company. They have been looking into the industry and believe the company is winning market share in the United States. Macquarie has an outperform rating and $241.00 price target on its shares. This compares to the latest Cochlear share price of $182.93.

Goodman Group (ASX: GMG)

Goodman Group is an integrated commercial and industrial property group. It owns, develops, and manages industrial real estate in 17 countries.

Goodman has been growing at a solid rate over the last decade thanks to the diversity of its operations and its exposure to quick growing markets such as ecommerce. This has resulted in strong demand from blue chip customers such as Amazon, Coles Group Ltd (ASX: COL) and Walmart, which appears to have positioned Goodman for sustainable growth over the 2020s.

One broker that is positive on its growth prospects is Morgan Stanley. It has been pleased with Goodman’s development work, high occupancy rates, and the yields it is commanding. In light of this, it has an overweight rating and $20.90 price target on its shares. This compares to the current Goodman share price of $18.07.

More reading

• 3 quality SaaS ASX shares to buy
• How this ASX REIT finished 2020 in positive territory
• Infinite games: 3 ASX shares with long-term visions
• 2 ASX blue chip shares tipped as buys for 2021
• 3 ASX shares to buy for 2021 and beyond

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. The Motley Fool Australia has recommended Cochlear Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post 2 of the best blue chip ASX shares to buy today appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/2MTLITR

The Cobalt Blue Holdings Ltd (ASX: COB) share price has rocketed to a 52-week high today, after the company responded to the ASX regarding its share price movements recently.

In today’s mid-session release, the company denied any knowledge of insider information that might have caused the share price to surge recently, notably a 14% spike on 8 January.

Following the release, the Cobalt Blue share price shot up 42% to 35.5 cents before closing at 34 cents.

Why did the Cobalt Blue share price surge today?

On 8 January, Cobalt Blue received a “please explain” from the ASX after shares in the company jumped almost 14% despite no news being announced.

The company today advised that it was “not aware of any explanation for the price change and increase in volume in the securities of Cobalt Blue, other than as referred to in previous ASX announcements”.

However, the company noted there were a number of factors that could explain investor interest in Cobalt Blue securities.

The company said that cobalt was a critical ingredient for high-performance lithium-ion batteries, which in turn are used globally to power electric vehicles (EV) and energy storage systems (ESS).

As many countries move towards clean energy, more subsidies on EV vehicles are being rolled out. These are significant, effectively subsidising between 20% to 35% of the purchase price of EVs in the European Union, for example – and turning the bloc into the largest global market in EV.

The company also said that the upcoming Biden Clean Energy plan in the United States includes a US$400 billion investment supporting the roll out of 25 million EVs, which will be another tailwind for the company.

In addition, the cobalt market has increased significantly from US$12/lb in April 2020, to more than US$19/lb at this time. It believes the cobalt price is on track to retrace its four-year longer-term average price of US$25/lb.

And finally, Cobalt Blue says that its Broken Hill-based Pilot Plant is on track to operate from February 2021, as already announced to the market on 21 December 2020.

About the Cobalt Blue share price

Before today’s surge, the Cobalt Blue share price has risen by almost 78% in the last 12 months. Including today’s move, the share price has increased 115% in that period.

The Cobalt Blue commands a market valuation of around $61 million.

More reading

• ASX 200 drops 0.9%
• Mesoblast (ASX:MSB) share price soars 14% on clinical trial results
• Fund manager tips 2 booming ASX miners for 2021 uranium bull market
• These 2 ASX healthcare shares popped today
• Ex-COO of ASX giant arrested in Sydney

Motley Fool contributor Eddy Sunarto has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Cobalt Blue (ASX:COB) share price shot up 42% this afternoon. Here’s why. appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/2Xv9yaA

The S&P/ASX 200 Index (ASX: XJO) fell by almost 0.9% today to 6,697 points.

Here are the highlights from the ASX:

Mesoblast Limited (ASX: MSB)

The Mesoblast share price went up 14% today after giving the market an update.

It announced today additional results from the landmark DREAM-HF randomised controlled phase 3 trial in 537 treated patients with chronic heart failure with reduced left ventricular ejection fraction (HFrEF) who received rexlemestrocel-L or control shame.

Mesoblast explained that a single dose of rexlemestrocel-L resulted in substantial and durable reductions in heart attacks, strokes and cardiac deaths.

The ASX 200 company said that existing therapies have only minimal or no benefit on these endpoints, these notable outcomes may signal a breakthrough in addressing the principal unmet needs in patients with chronic heart failure.

Based on the observed reduction in mortality and morbidity in this phase 3 trial, Mesoblast intends to meet with the FDA to discuss a potential approval pathway.

Magellan Financial Group Ltd (ASX: MFG)

The Magellan share price went up 1.4% after updating the market with its funds under management (FUM) for December 2020.

The fund manager revealed that its total FUM fell from $103 billion to $101.4 billion. The main part of the decline was a $2 billion decline of FUM in the global equities strategy.

Magellan said that, in December, it experienced net inflows of $579 million, included net retail inflows of $327 million and net institutional inflows of $252 million.

The ASX 200 fund manager reported that it is entitled to performance fees of approximately $12 million for the six months ended 31 December 2020. It stated that performance fees may fluctuate significantly from period to period.

Average FUM for the six months ended 31 December 2020 was almost $101 billion, this compares to average FUM of $92.8 billion for the six months ending 31 December 2019.

Magellan stated that the average exchange rate between the Aussie dollar and the US dollar for the six months ended 31 December 2020 was 0.7234, compared to 0.6848 for the six months ending 31 December 2019.

Shaver Shop Group Ltd (ASX: SSG)

The Shaver Shop share price went up 11.3% today after the grooming business gave a trading update and profit guidance for the first half of FY21.

Shaver Shop said that the sales for the second quarter of FY21 increased by 12.4% in total and 13.7% growth of like for like sales. Online sales growth was 64.7% in the second quarter, and this was the primary driver of sales.

FY21 first half online sales grew 102% helped like for sales grow by 17.3% and total sales went up 15.2%. Online sales represented 30.3% of total sales in the first half.

The gross profit margin is expected to increase by more than 200 basis points across the first half of FY21. The company tried to balance volume growth and profit margins.

FY21 first half net profit is expected to be between $13.5 million to $14 million, compared to $7.6 million in the prior corresponding period.

Shaver Shop managing director and CEO Cameron Fox said: “Our teams across Australia and New Zealand have remained focused and resilient and have consistently delivered exceptional customer service during an incredibly uncertain time. With in-store sales conversion more than 50% and average transaction values increasing more than 10%, our store teams were able to more than offset the 20% plus decline in outside foot traffic we saw in December.

“We expect our first half profit to increase 75% to 85% when we release our results in February and we are on track to deliver another record profit for the full year.”

More reading

• Mesoblast (ASX:MSB) share price soars 14% on clinical trial results
• Why the QBE (ASX:QBE) share price is in focus today
• ASX 200 down 0.4%: Afterpay tumbles, bank shares lower, gold miners crash
• The latest ASX “buy” recommendations from top brokers
• Why the SelfWealth (ASX:SWF) share price is on the rise this morning

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post ASX 200 drops 0.9% appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3nsj2Og

The Mesoblast Limited (ASX: MSB) share price rocketed on news that the company’s drug, rexlemestrocel-L, is showing promising signs.

The Mesoblast share price closed today’s trade 14.29% higher at $2.56 per share. Notably, today is the highest its shares have been since the failure of remestemcel-L in treating COVID-19 patients was announced in late December.

Why is the Mesoblast share price soaring?

Mesoblast announced that a single dose of its drug rexlemestrocel-L provides a reduction in heart attacks, strokes and cardiac death in patients with chronic heart failure.

The results come from its landmark, randomised controlled phase 3 trial with 537 patients. Of the patients, who all had chronic heart failure, some received rexlemestrocel-L and others received a control sham. The study found that a single dose of the drug resulted in a substantial and durable reduction in heart attacks, strokes, and cardiac deaths. The patients were monitored for 30 months after the dose was administered.

Since the existing therapies have very minimal benefit on these same endpoints, Mesoblast claims that these results may signal a breakthrough in addressing certain unmet needs with patients who have chronic heart failure.

Heart attacks and strokes were reduced by 60% from a single dose, while incidence of death from rexlemestrocel-L was also reduced by the same amount. Across the board the drug reduced all 3 outcomes of death by 30%.

This comes as a sharp turnaround from the news Mesoblast released on 15 December that there was no reduction in the recurrent non-fatal decompensated heart failure events from the drug, which caused its share price to fall by 15%.

Chronic heart failure affects 6.5 million people in the US and 26 million globally, with those numbers increasing in prevalence and incidence every year.

About the Mesoblast share price

The Mesoblast share price was particularly volatile in 2020, rising as high as $5.70 and dropping as low as $1.02. Nonetheless the recent news has pushed shares in the company higher, resulting in a 1-year return of 11.79%.

More reading

• ASX 200 drops 0.9%
• These are the 10 most shorted shares on the ASX
• Mesoblast (ASX:MSB) share price could be facing more pressure in 2021
• Do ASX mining companies carry the Australian share market?
• These are the 10 most shorted shares on the ASX

Motley Fool contributor Daniel Ewing has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Mesoblast (ASX:MSB) share price soars 14% on clinical trial results appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/2Xv8TWE

ASX uranium shares are once again becoming a hot topic.

Somewhat ironically, investing in uranium miners is controversial in Australia. I say that because Australia is believed to have the world’s largest uranium resources. At least for resources that are recoverable at a reasonable cost.

Yet with no nuclear power generation of its own, and no nuclear-powered naval vessels, many Aussie investors view uranium as a dangerous energy source best relegated to the last century.

Now there are good reasons to be cautious around uranium. It can, after all, be enriched for use in nuclear missiles. And the waste remains radioactive for many centuries.  

On the flipside, however, uranium produces power without any carbon emissions. And in a world intent on de-carbonising without turning off the power, some analysts are forecasting a fresh bull run for uranium.

The case for a 2021 uranium bull market

Ben Cleary is a portfolio manager at Tribeca Investment Partners. Cleary has a decidedly bullish outlook for many hard commodities this year. And, as the Australian Financial Review reports, Cleary believes uranium could enter a bull market in 2021.

According to Cleary:

Things like uranium, which have no carbon footprint, are starting to get some recognition. Oil can double, uranium can go up five times. It’s that structural demand and supply mismatch – last year, for example, there was 200 million pounds of [uranium] consumption and 100 million pounds was mined.

The difference between what was consumed and what was mined was made up from existing stockpiles. But those stockpiles will only last so long if demand remains in excess of new supply. Economics 101 dictates that any prolonged period of excess demand without a matching increase in supply will drive prices higher.

Cleary tipped 2 All Ordinaries Index (ASX: XAO) uranium miners he believes are well-placed to benefit from an increase in uranium prices: Bannerman Resources Limited (ASX: BMN) and Boss Energy Ltd (ASX: BOE).

Boss Energy and Bannerman Resources share price and company snapshots

Boss Energy (formerly Boss Resources) holds interests in the Honeymoon uranium project located in South Australia.

The Boss Energy share price fell hard today, down 9.0%. That leaves it flat for the 2021 calendar year. Over the past 12 months, though, Boss Energy shares have gained 100%.

Bannerman Resources focuses on the development of large open-pit uranium operations. The majority of its interest are in the Etango Uranium Project in Namibia, Africa.

The Bannerman Resources share price also dropped today, down 7.7%. Shares are still well into the green for the year though, up 20% since 4 January. Over the past 12 months Bannerman Resources shares have gained a whopping 200%.

More reading

• These 2 ASX healthcare shares popped today
• Ex-COO of ASX giant arrested in Sydney
• It’s electrifying: Vulcan Energy (ASX:VUL) share price up 23% today
• Genesis Energy (ASX:GNE) share price drops 5% today after closing at 52-week high last week
• The Marley Spoon (ASX:MMM) share price is up over 700% in 12 months

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Fund manager tips 2 booming ASX miners for 2021 uranium bull market appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/2MMLzBn

The All Ordinaries Index (ASX: XAO) slid down close to a percent today, with the healthcare sector doing the same. At the time of writing, the All Ords is down 0.96% and the healthcare sector has dipped 1.2%.

Regardless of this lacklustre performance, these 2 ASX healthcare shares are having a pretty good day. 

Anteris Technologies Ltd (ASX: AVR)

The Anteris share price has surged 18.60% today to reach $5.10 per share. This gain comes after a tough year, with the Anteris share price dropping more than 62% over the past 12 months.

The company’s mission is to create the world’s most durable heart valve. While no significant news hit the wires today, the company continues to steadily progress its heart valve technology.

In March 2020, Anteris announced the first implantation of its ADAPT-treated single-piece 3D aortic valve in a patient with aortic stenosis.

At the start of this year, the company confirmed that it had entered into a short-term facility for a $1,220,000 advance, based on its forecasted research & development (R&D) tax incentive. Anteris followed this statement up two days later announcing an additional $20 million in secured funding.

According to Anteris, the company continues to focus on delivering “next generation technologies that help healthcare professionals create life-changing outcomes for patients.”

CleanSpace Holdings Ltd (ASX: CSX)

The CleanSpace Holdings share price is currently up by 7.29%, trading at $7.51 at the time of writing. The company engages in the design and manufacturing of respiratory protection equipment (RPE) for healthcare and industrial employers internationally.

The purpose of RPE is to protect people from inhaling hazardous substances in the air. The Sydney-based company was founded by a team of biomedical engineers in 2009. Products sold by CleanSpace include the CleanSpace Halo for the healthcare market and the CleanSpace2, CleanSpace Ultra and CleanSpace Ex designed for industrial markets. 

While it’s been a rocky ride over the previous 12-month period, the CleanSpace share price has just managed to inch into the green, returning 0.67% over the past year.

In its most recent trading update, CleanSpace upgraded its first half FY21 revenue expectations to be in the range of $39 million–$41 million for the six months ended 31 December 2020.

More reading

• 2 more small cap ASX shares to watch in 2021
• Why the CleanSpace (ASX:CSX) share price is climbing today

Motley Fool contributor Gretchen Kennedy has no position in any of the stocks mentioned. The Motley Fool Australia has recommended CleanSpace Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post These 2 ASX healthcare shares popped today appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3nytovS